Treatments for diabetic neuropathy
- PMID: 12643108
- DOI: 10.1007/s11892-001-0024-8
Treatments for diabetic neuropathy
Abstract
The management of symptomatic diabetic sensory neuropathy presents a therapeutic challenge to the practicing physician. Two approaches are outlined in this article. First, symptomatic therapies, which will not influence the natural history of painful neuropathy, are discussed. These include, in addition to the stable glycemic control, tricyclic drugs, a number of anticonvulsant and antiarrhythmic agents, and opioid-like medications. Topical therapies and nonpharmalogic approaches are also discussed. With the exception of near normoglycemia, treatments that may slow the progression of neuropathy are experimental and include aldose reductase inhibitors, antioxidants, and other agents. Finally, the approach to patients without symptoms but with sensory loss is discussed.
Similar articles
-
Standard and emerging treatment options for diabetic neuropathy.Curr Pharm Des. 2014;20(22):3689-704. doi: 10.2174/13816128113196660682. Curr Pharm Des. 2014. PMID: 24040869 Review.
-
Medical evaluation and treatment of diabetic peripheral neuropathy.Clin Podiatr Med Surg. 2003 Oct;20(4):671-88. doi: 10.1016/S0891-8422(03)00068-5. Clin Podiatr Med Surg. 2003. PMID: 14636032 Review.
-
Choosing drugs for the treatment of diabetic neuropathy.Expert Opin Pharmacother. 2015;16(12):1805-14. doi: 10.1517/14656566.2015.1067680. Epub 2015 Jul 10. Expert Opin Pharmacother. 2015. PMID: 26161591 Review.
-
Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management.Diabetes Metab Res Rev. 2011 Oct;27(7):629-38. doi: 10.1002/dmrr.1225. Diabetes Metab Res Rev. 2011. PMID: 21695762
-
Newer agents for the treatment of painful diabetic peripheral neuropathy.Curr Diab Rep. 2005 Dec;5(6):409-16. doi: 10.1007/s11892-005-0047-7. Curr Diab Rep. 2005. PMID: 16316590 Review.
Cited by
-
[Colorectal cancer 2D-proteomics: identification of altered protein expression].Mol Biol (Mosk). 2009 Mar-Apr;43(2):348-56. doi: 10.1134/s0026893309020186. Mol Biol (Mosk). 2009. PMID: 19425502 Russian.
-
Epalrestat, an aldose reductase inhibitor, in diabetic neuropathy: an Indian perspective.Ann Indian Acad Neurol. 2008 Oct;11(4):231-5. doi: 10.4103/0972-2327.44558. Ann Indian Acad Neurol. 2008. PMID: 19893679 Free PMC article.
-
Update on the pathogenesis of diabetic neuropathy.Curr Diab Rep. 2003 Dec;3(6):439-45. doi: 10.1007/s11892-003-0005-1. Curr Diab Rep. 2003. PMID: 14611738 Review.
-
Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat.Diabet Med. 2008 Jul;25(7):818-25. doi: 10.1111/j.1464-5491.2008.02490.x. Diabet Med. 2008. PMID: 18644069 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical